What Has Been the Growth Trajectory for the Systemic Aspergillosis And Systemic Candidiasis Market in Recent Years?
The systemic aspergillosis and systemic candidiasis market has seen considerable growth due to a variety of factors.
•Over the past few years, there has been a consistent growth in the market size of systemic aspergillosis and systemic candidiasis. The market, currently valued at $7.24 billion in 2024, is projected to increase to $7.59 billion in 2025, registering a compound annual growth rate (CAGR) of 4.8%.
This growth during the historical period can be credited to factors such as an increasing number of fungal infection cases, patient population with compromised immunity, better diagnostic technologies, an increase in invasive medical procedures, and a global increase in infections.
How Does the Forecast Look for the Systemic Aspergillosis And Systemic Candidiasis Market?
The systemic aspergillosis and systemic candidiasis market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for systemic aspergillosis and systemic candidiasis is forecasted to demonstrate robust growth in the upcoming years, potentially reaching $9.28 billion by 2029, with a compound annual growth rate (CAGR) of 5.1%.
This predicted growth during the forecast period can be linked to global initiatives in antifungal resistance surveillance, the increasing age of the populace, the adoption of telemedicine for remote consultations, patient-oriented drug development, and digital health platforms for patient management. Key trends to be on lookout for during the forecast period include the development of new fungal biomarkers for early identification, the introduction of innovative antifungal agents, breakthroughs in immunotherapy, and the emergence of creative drug delivery systems.
What Are the Critical Driver Fuelling the Systemic Aspergillosis And Systemic Candidiasis Market's Growth?
The growth of the systemic aspergillosis and systemic candidiasis market is set to accelerate due to the mounting prevalence of fungal diseases. Fungal diseases, characterized by infections caused by fungi, can impact several parts of the body and give rise to a range of symptoms and complications. Types of these diseases encompass cutaneous skin infections, respiratory infections and systemic infections. These diseases are generally managed with antifungal medications like oral azoles, voriconazole and liposomal amphotericin B. The Lancet, an esteemed London-based medical journal, reported in July 2024 that the estimates suggest some 6.5 million cases of invasive fungal infections occur every year. These infections lead to approximately 3.8 million deaths, with direct infection being the cause of roughly 2.5 million of these deaths. Hence, the burgeoning prevalence of fungal diseases is fuelling the expansion of the systemic aspergillosis and systemic candidiasis market.
How Is the Systemic Aspergillosis And Systemic Candidiasis Market segmented?
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole
2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines
5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents
Pre-Book The Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Systemic Aspergillosis And Systemic Candidiasis Market?
Top-tier businesses in the systemic aspergillosis and systemic candidiasis markets are focusing on the creation of innovative products, including echinocandins, to increase treatment effectiveness and tackle the rising problem of antifungal resistance. Echinocandins, an antifungal drug type, obstruct the creation of ß-glucan, a key component in the composition of fungal cell walls. For example, in March 2023, two U.S. biotechnology firms, Cidara Therapeutics and Melinta Therapeutics, received clearance from the U.S. Food and Drug Administration (FDA), an agency tasked with public health protection, for REZZAYO (rezafungin for injection). Developed to ease administration, REZZAYO (rezafungin for injection) is a new once-weekly echinocandin for addressing candidemia in adults with few or no other treatment choices. The once-a-week dosage regimen of REZZAYO simplifies the treatment process, and promotes continuity of care for patients suffering from invasive candidiasis, especially those in a hospital environment where successful infection control is vital.
Who Are the Key Players in the Systemic Aspergillosis And Systemic Candidiasis Market?
Major companies operating in the systemic aspergillosis and systemic candidiasis market include:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Sanofi S.A.
• GlaxoSmithKline PLC
• Gilead Sciences Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Matinas BioPharma Holdings Inc.
• Shionogi & Co. Ltd
• Cipla Limited
• Taj Pharmaceuticals Limited
• Basilea Pharmaceutica Ltd.
• Cidara Therapeutics Inc.
• T2 Biosystems Inc.
• Sandoz International GmbH
• Grupo Ferrer International S.A.
• Entasis Therapeutics Inc.
• F2G Ltd.
• Mycovia Pharmaceuticals Inc.
• ContraFect Corporation
• Enzon Pharmaceutical Inc.
• Pacgen Life Science Corporation
• Biosergen AS
• N8 Medical LLC
What Is The Most Dominant Region In The Systemic Aspergillosis And Systemic Candidiasis Market?
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
